Fusion Protein / Bispecific Antibody DS Release Specific Testing

Fusion protein and bispecific antibody DS release specific testing is a core quality attribute service for complex biologics such as Fc fusion proteins and bispecific antibodies (BsAb). It systematically characterizes mispairing variants, glycosylation profiles, and aggregation tendency, with methods designed to align with ICH Q6B and global regulatory standards.

Fusion proteins (especially Fc fusions) and bispecific antibodies represent the next generation of biologics. As of August 2025, 17 multispecific antibodies have been approved by the FDA and/or EMA for clinical use, with 399 ongoing clinical studies. Compared to traditional monoclonal antibodies, these molecules have higher structural complexity, posing unique challenges for analytical characterization and CMC quality control. Fc fusion proteins extend in vivo half‑life by fusing a therapeutic protein to an antibody Fc domain. Bispecific antibodies simultaneously target two different antigens or epitopes, enhancing specificity and reducing toxicity. However, this complexity brings higher risks of mispairing, complex glycosylation patterns, and aggregation tendency.

Creative Biogene provides one‑stop services from DS release testing to IND/BLA submission data packages, designed to align with ICH Q6B and industry best practices, including method development, validation, and transfer.

Technical Principles & Test Methods

Mispairing Variant Detection

Bispecific antibody assembly in cells is highly complex, generating numerous unintended mispairing variants including homodimers, light chain mispairing, heavy chain mispairing, half antibodies, and deletion variants. These impurities reduce yield and may cause unintended immunogenicity or toxicity, requiring strict monitoring during product release. Unlike mAbs, the molecular weight difference between the intended BsAb and mispaired variants can be as small as a few daltons, with minimal physicochemical differences, making conventional chromatography insufficient. High‑resolution mass spectrometry is essential.

Method 1: LC‑MS Intact Mass Analysis

High‑resolution MS (Q‑TOF or Orbitrap) accurately measures the molecular weight of intact antibody molecules. Different mispairing variants have distinct exact masses due to differences in amino acid composition. Deconvolution identifies each component’s mass, compares to theoretical masses to determine variant identity, and estimates relative abundance from signal intensity.

Method 2: LC‑MS/MS Peptide Mapping

The BsAb is digested with trypsin or other proteases. The resulting peptide mixture is separated by reversed‑phase liquid chromatography and analyzed by tandem MS (MS/MS). Identification of specific peptides localizes mispairing sites (e.g., junction regions of different chains), confirming mispairing type at the molecular level. This method is particularly suitable for asymmetric bispecific antibodies.

Method 3: CE‑SDS (Reduced / Non‑reduced)

CE‑SDS separates proteins by molecular weight. Non‑reduced CE‑SDS distinguishes intact antibodies, half antibodies, and heavy chain dimers. CE‑SDS is widely used for identifying mispairing impurities in BsAbs.

Glycosylation Profiling

Glycosylation is one of the most critical post‑translational modifications for Fc fusion proteins and bispecific antibodies, directly affecting stability, immunogenicity, and pharmacokinetics. Fc fusion proteins often introduce abundant N‑glycans and O‑glycans to extend half‑life, but this high heterogeneity poses analytical challenges. Regulators require glycosylation profiling of therapeutic proteins as a product quality attribute (PQA) or critical quality attribute (CQA).

Method 1: LC‑MS/MS Glycopeptide Mapping (N‑glycan / O‑glycan)

The protein is digested with trypsin, and glycopeptides are separated by reversed‑phase chromatography. Tandem MS simultaneously identifies peptide sequence and attached glycan structure. Novel fragmentation techniques such as electron‑activated dissociation (EAD) generate rich peptide backbone fragments and glycan fragments, enabling precise localization of glycosylation sites and high‑confidence identification.

Method 2: AEX‑MS Intact Glycoprotein Analysis

Anion exchange chromatography separates glycoforms based on surface charge differences (e.g., sialylation level), coupled online with MS for intact glycoprotein analysis. This technique has successfully separated 9 chromatographic peaks and identified 268 protein forms for highly glycosylated Fc fusion proteins.

Method 3: HILIC‑UPLC‑FLR – Relative Quantitation of Released N‑glycans

N‑glycans are released by PNGase F, labeled with a fluorescent dye (2‑AB or 2‑AA), separated by hydrophilic interaction chromatography (HILIC), and quantified by fluorescence detection. Suitable for routine release testing of glycan profiles.

Aggregation Tendency Assessment

Aggregation is one of the most common degradation pathways for therapeutic proteins. Aggregates can increase immunogenicity by activating the immune system, affecting product safety and efficacy. The multi‑domain nature of Fc fusion proteins and bispecific antibodies often results in higher aggregation tendency compared to mAbs, requiring strict monitoring at DS release.

Method 1: SEC‑HPLC

Size‑exclusion chromatography separates molecules based on hydrodynamic volume. Aggregates (dimers, multimers) elute before the monomer; fragments (degradation products) elute after the monomer. Performed under native conditions to preserve protein conformation.

Method 2: CE‑SDS (Non‑reduced)

CE‑SDS separates proteins by molecular weight under denaturing conditions and serves as an orthogonal method to SEC‑HPLC. Non‑reduced CE‑SDS detects covalent aggregates and fragments, complementing SEC‑HPLC for covalent aggregate detection.

Regulatory Basis

Advantages

• Full coverage of three CQA modules: mispairing identification/quantitation, in‑depth glycosylation profiling, and aggregation tendency assessment.
• High‑resolution LC‑MS for mispairing: resolution ≥30,000 distinguishes variants differing by only a few daltons; simultaneous detection of homodimers, half antibodies, light chain mispairs, and other impurities.
• CE‑SDS dual function: non‑reduced CE‑SDS detects covalent aggregates, fragments, and mispairing variants (e.g., half antibodies); serves as an ideal orthogonal method to SEC‑HPLC.
• Multi‑dimensional glycosylation analysis: released N‑glycans by HILIC‑FLR (relative quantitation) + LC‑MS/MS glycopeptide mapping (site‑specific) + AEX‑MS (intact glycoprotein).
• SEC‑HPLC as primary aggregation method: optimized for high‑resolution separation of monomers, HMW aggregates, and LMW fragments; full validation per ICH Q2(R1)/Q2(R2).
• ICH Q6B full validation: all methods validated covering specificity, precision, accuracy, linearity, range, and robustness.
• Orthogonal strategy: SEC‑HPLC (native) + CE‑SDS (denaturing) for aggregation; LC‑MS intact mass + RP‑UPLC + CE‑SDS for mispairing cross‑validation.

Contact Us

For a customized DS release testing strategy, method validation, or IND/BLA submission support for your fusion protein or bispecific antibody product, contact Creative Biogene’s technical team.

FAQ